ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 2811 • 2014 ACR/ARHP Annual Meeting

    Improvements in Rheumatoid Arthritis Related Fatigue Are Driven By Reductions in Pain, Not Disease Activity – Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Katie L Druce1, Gareth T Jones2, Gary J. Macfarlane1 and Neil Basu1, 1Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Musculoskeletal Research Collaboration (Epidemiology Group),, University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients commonly report reductions in fatigue after commencing Anti-TNF therapy. The mechanisms behind such reductions have not been determined, although it…
  • Abstract Number: 2086 • 2014 ACR/ARHP Annual Meeting

    Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis

    Antonio Gonzalez1, Aida Ferreiro-Iglesias2, Juan Gomez-Reino3 and on Behalf of Their Collaborators4, 1Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 2Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 3Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 4multiple, multiple, Spain

    Background/Purpose The use of biomarkers to predict response to the different drugs available for treating rheumatoid arthritis (RA) is a very desirable goal. However, success…
  • Abstract Number: 823 • 2014 ACR/ARHP Annual Meeting

    Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol

    Alina Soare1, Carina Mihai2, Ana Maria Gherghe2, Rucsandra Dobrota2, Raida Oneata2, Simona Pintilie2, Mihaela Milicescu2, Ioan Ancuta2, Andrei Martin2, Mariana Sasu2, Claudia Ciofu2, Liviu Macovei2, Victor Stoica2 and Mihai Bojinca2, 1internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, 2Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania

    Background/Purpose Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi), especially in countries with a high TB burden.  Careful TB screening is…
  • Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy

    Karen Hambardzumyan1, R.J. Bolce2, Saedis Saevarsdottir3, Kristina Forslind4, Ingemar F. Petersson5, Pierre Geborek6, Eric H. Sasso2, David Chernoff2, Scott Cruickshank7 and Ronald F. van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 7Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 8Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden

    Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…
  • Abstract Number: 2587 • 2014 ACR/ARHP Annual Meeting

    Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis

    Pauline Manicki1, Jacques Morel2, Bernard Combe3 and Cédric Lukas4, 1immuno-rhumatologie, Hôpital Lapeyronie, Montpellier, France, 2Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 3Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 4Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France

    Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis. Background/Purpose: TNF blockers have demonstrated substantial clinical efficacy in spondyloarthritis…
  • Abstract Number: 1741 • 2014 ACR/ARHP Annual Meeting

    Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation

    Thomas Andersen1, René Østgård1,2, Bent Deleuran1,2, Malene Hvid3 and Henning Glerup4, 1Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, 2Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, 4Dept. of Gastroenterology, Regional Hospital of Silkeborg, Silkeborg, Denmark

    Background/Purpose The pro-inflammatory Th17 associated cytokines IL-17A and IL-22 have been proposed as important mediators of the inflammation seen in spondyloarthritis (SpA) and inflammatory bowel…
  • Abstract Number: 576 • 2014 ACR/ARHP Annual Meeting

    Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis (axSpA) Are Related to Disease Duration

    Victoria Navarro-Compán1, Enrique Melguizo-Madrid2, Concepción González-Rodríguez3, Federico Navarro-Sarabia4 and Rafael Ariza-Ariza4, 1Rheumatology, University Hospital La Paz and Leiden University Medical Center, Madrid, Spain, 2Biochemistry, University Hospital Virgen Macarena, Sevilla, Spain, 3University Hospital Virgen Macarena, Sevilla, Spain, 4Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain

    Background/Purpose: Tumor necrosis factor (TNF) alpha is responsible for induction of dkk-1 which down-regulates bone formation. Therefore, it was expected that TNF-blocker therapy would inhibit…
  • Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting

    Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis

    Jocelyn H. Leu1, Alan M. Mendelsohn2, Joyce Ford1, Hugh M. Davis1, Honghui Zhou1 and Zhenhua Xu1, 1Janssen Research & Development, LLC., Spring House, PA, 2Immunology, Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations  of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…
  • Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting

    Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures

    M.a.C. van der Weijden1,2, J.C. van Denderen2, W.F. Lems1, M.T. Nurmohamed1,2, B.a.C Dijkmans1,2 and I.E. van der Horst-Bruinsma1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…
  • Abstract Number: 1603 • 2014 ACR/ARHP Annual Meeting

    Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients

    Alejandro Villalba1, Chamaida Plasencia-Rodriguez1, Diana Peiteado1, Laura Nuño2, Gema Bonilla3, Alejandro Balsa4, Emilio Martín-Mola5 and Dora Pascual-Salcedo6, 1Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 2Hospital La Paz-IdiPaz, Madrid, Spain, 3Rheumatology, Hospital La Paz, Madrid, Spain, 4Reumatology, Hospital Universitario La Paz, Madrid, Spain, 5Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 6Immunology, La Paz University Hospital, Madrid, Spain

    Background/Purpose: The spondyloarthritis (SpA) patients treated under TNF inhibitors (TNFi)  with detectable antidrug antibodies (ADA) often develop  loss of efficacy. Concomitant therapy with  methotrexate (MTX)…
  • Abstract Number: 573 • 2014 ACR/ARHP Annual Meeting

    Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF-Inhibitors

    Salima F.E. van Weely1, Eva L. Kneepkens1, Mike T. Nurmohamed1, Joost Dekker1,2 and Irene E. van der Horst-Bruinsma3, 1Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, 2Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Currently, only limited information is available on the long-term course of limitations in physical functioning and spinal mobility in Ankylosing Spondylitis (AS) patients receiving…
  • Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting

    Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers

    Rebecca Davies1, Lianne Kearsley-Fleet1, Eileen Baildam2, Michael W. Beresford3, Helen E. Foster4, Taunton R. Southwood5, Wendy Thomson6, Kimme L. Hyrich7, on Behalf Of The BSPAR Etanercept Cohort Study1 and The Biologics for Children with Rheumatic Diseases (BCRD) study1, 1Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, 3Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 5Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, 6Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 7Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…
  • Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting

    The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis

    Michael J. Nissen1, Adrian Ciurea2, Juerg Bernhard3, Rudiger Muller4, Giorgio Tamborrini5, Martin Toniolo6, Cem Gabay7 and Axel Finckh1, 1Rheumatology, Geneva University Hospital, Geneva, Switzerland, 2Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, 3Rheumatology, Solothurn Hospital, Solothurn, Switzerland, 4Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 5Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, 6Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, 7University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland

    Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
  • Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)

    Saedis Saevarsdottir1, Michele Santacatterina2, Carl Turesson3, Helena Forsblad4, Lennart Jacobsson4 and Staffan Lindblad5, 1Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 5Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
  • Abstract Number: 572 • 2014 ACR/ARHP Annual Meeting

    Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests

    Salima F.E. van Weely1, Joost Dekker1,2, Martijn P.M. Steultjens3, Christiaan J. Van Denderen1, Mike T. Nurmohamed1, Ben A.C. Dijkmans4 and Irene E. van der Horst-Bruinsma4, 1Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, 2Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, 3Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, 4Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Physical functioning is considered an important outcome domain for the evaluation of the effectiveness of therapy and the course of the disease. In an effort…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology